This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
7 Jan 2013

Asymmetric Catalysis Allows Controlled Synthesis of Biologically Active Molecules

For his outstanding research contributions to catalytic processes in synthesis of biologically active molecules, Professor Dr Nicolai Cramer is receiving the BASF Catalysis Award 2013. Professor Cramer heads the laboratory of asymmetric catalysis and synthesis at the École Polytechnique Fédérale (EPF) in Lausanne, Switzerland. The prize, worth €10,000, was presented by Dr. Andreas Kreimeyer, Member of the Board of Executive Directors of BASF SE and Research Executive Director, at the “Heidelberg Forum of Molecular Catalysis,” a symposium of international experts organized jointly by Heidelberg University, Collaborative Research Center 623 “Molecular Catalysts” and BASF SE.

 

“Catalysis is an important key technology for the chemical industry and is an indispensable tool for accessing new feedstocks and developing new energy efficient production processes,” said Kreimeyer. As a company with a leading international research and development platform for catalysts, BASF therefore attaches particular importance to promoting excellent young researchers in this field.

 

With his research group centered at EPF Lausanne, Professor Cramer is working particularly in the field of enantioselective metal-catalyzed transformations and their implementation for the synthesis of complex biologically active molecules. The Cramer lab works on the development of broadly applicable catalytic methods for the selective functionalization of relatively inert C-H and C-C bonds with different transition-metal complexes.

 

“We are developing precise tools for all fields that produce molecules with high reactivity and selectivity. Our methods are suited for a faster synthesis because in medical research it is also essential to produce possible active ingredients rapidly. In this way, we have synthesized and identified molecules that show an anti-HIV effect. In doing this we closely collaborate with the life sciences faculty in Lausanne,” explained the prize winner Nicolai Cramer. “But other interesting fields also exist such as material sciences in which we can provide a better approach to molecules that for example are used for organic electronics.”

 

The “Heidelberg Forum of Molecular Catalysis,” an international scientific symposium of top class researchers based at Heidelberg University, is being held this year for the seventh time. The event offers scientists from academia and industry the opportunity to exchange news and information about the latest research activities in molecular catalysis. Plenary presentations are being held this year not only by the prizewinner but also by Professors Stephen L. Buchwald, MIT, Cambridge, Massachusetts, Peter Chen, ETH Zürich, Switzerland, and the Nobel Prize laureate Ei-ichi Negishi, Purdue University, Indiana.

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.